Hormonal Contraceptives Market is anticipated to Display Substantial Growth in the Forecast period 2021-2028
Hormonal Contraceptives Market |
Hormonal contraceptives contain
either a progestin (progesterone medication) or an oestrogen. Both progestin
and oestrogen are synthesised in a laboratory and are comparable to the
hormones produced naturally by all women. These two hormones, or the progestin
alone, are used to prevent pregnancy in a variety of ways, including preventing
ovulation (egg release), thickening the mucus around the cervix (uterine
mouth), preventing sperm from entering the uterus (uterus), and thinning the
inner wall of the uterus (uterus) to prevent the attachment of fertilised eggs.
Over the projected period, the
rising number of unwanted pregnancies is likely to fuel market growth. During
the projected period, the increasing number of unwanted pregnancies is likely
to drive the growth of the worldwide hormonal contraceptives market. According
to a PubMed publication, the number of unwanted pregnancies in the United
States is roughly three million each year. As a result, the Center for Medicaid
and CHIP Services (CMCS) launched a Maternal and Infant Health Initiative for
the Medicaid and Children's Health Insurance Program (CHIP) to encourage the
use of effective contraceptive methods and assist women in avoiding such
pregnancies.
According to Coherent Market Insights, The global Hormonal
Contraceptives Market is estimated to be US$ 15,232.2 Million in
2021 and is expected to reach US$ 18,577.6 million by 2028, at a CAGR of 2.9%
during the forecast period (2021 –2028).
The worldwide hormonal
contraceptives market is divided into product, hormone, age group, end user,
and geographic segments. Oral contraceptive pills, injectable birth control,
emergency contraceptive tablets, vaginal rings, and transdermal patches
dominate the market. It is classified as progestin-only contraceptive or
combination hormonal contraceptive based on hormones. It is separated into four
age groups: 15-24 years, 25-34 years, 35-44 years, and over 44 years. It is
classified according to end user into hospitals, households, and clinics. It is
divided into four regions: North America, Europe, Asia-Pacific, and Latin
America and the Caribbean.
Because of the existence of
significant market participants, the high incidence of unwanted pregnancies,
high per capita income, and rising government efforts, North America is
expected to dominate the worldwide market throughout the projection period. The
wealthy nations of Europe, such as the United Kingdom and Germany, have a
strong healthcare infrastructure and a high level of knowledge of hormonal
contraception, which is predicted to increase regional growth. Asia Pacific is
expected to increase rapidly in the next years due to a rising number of women
of reproductive age and significant unmet requirements.
Because of the increased emphasis
on family planning and the need to avoid unwanted pregnancy, the hormonal
contraceptive market is likely to rise significantly over the forecast period.
Primary drivers driving market expansion include health risks connected with
adolescent pregnancies, increased knowledge of contemporary contraceptive
techniques, and an increase in the usage of oral tablets as a key tool to
prevent unexpected pregnancy, all of which fuel market growth. However, the
availability of other contraceptive techniques, the health hazards connected
with contraceptive usage, and a lack of societal acceptance are projected to
limit the expansion of the hormonal contraceptives industry.
Major Companies Listed are- Mayer Laboratories, Merck & Co., Inc.,
Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile
Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun
Pharmaceutical Industries Ltd., and Cipla Limited.
Comments
Post a Comment